摘要
目的探讨阿立哌唑与喹硫平对首发精神分裂症患者临床疗效及认知功能的影响。方法将82例首发精神分裂症患者随机分为两组，研究组42例，口服阿立哌唑治疗，对照组40例，口服喹硫平治疗，观察8周。于治疗前及治疗第1周、4周、8周末采用阳性与阴性症状量表评定临床疗效；于治疗前及治疗8周末，采用韦氏记忆量表中的再认、图片、联想及背数分量表评定认知功能。结果治疗后两组阳性与阴性症状量表评分均较治疗前有显著下降（P〈0．01），同期两组评分比较差异均无显著性（P〉0．05）。治疗8周末，两组韦氏记忆量表再认、图片、联想、背数分量表评分均较治疗前显著提高（P〈0．05或0．01），但研究组较对照组提高更显著（P〈0．05或0．01）。结论阿立哌唑与喹硫平治疗首发精神分裂症患者疗效显著且相当，但阿立哌唑改善患者的认知功能优于喹硫平。
Objective To explore the influences of aripiprazole and quetiapine on clinical efficacy and cognitive function of schizophrenics. Methods Eighty-two first-episode schizophrenics were randomly assigned to research group （n=42） took orally aripiprazole and control group （n=40） did quetiapine for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） at baseline and the end of the 1^st, 4^th and 8^th week and cognitive function with the Recognition, Picture, Association and Digit Span subscale of the Wechsler Memory Scale （WMS） at baseline and the end of the 8＊h week. ResuLts After treatment the PANSS scores of both groups lowered more significantly compared with pretreatment （P〈0.01） and there were no significant differences in contemporaneous group comparisons （P〉0.05）. At the end of the 8^th week, Recognition, Picture, Association and Digit Span scores of both groups increased more significantly （P〈0.05 or 0.01）, so did those in research than in control group （P〈0.05 or 0.01）. Conclusion Both aripiprazole and quetiapine are highly effective against first-episode schizophrenia, but the former has an advantage in improving patients＇ cognitive functions over the latter.
出处
《临床心身疾病杂志》
CAS
2012年第6期506-508,共3页
Journal of Clinical Psychosomatic Diseases
